Imaging of CB1 Receptors Using (11C)SD5024
Stopped early · Phase 1
Conditions studied: Healthy
In brief
Background: \- The cannabinoid type 1 (CB1) receptor is a protein found on some brain cells. It may play a role in obesity or some psychiatric disorders such as schizophrenia. Imaging studies like positron emission tomography (PET) can show where CB1 receptors are located. A new radioactive chemical, 11C-SD5024, may be able to show these receptors more clearly than previous radioactive chemicals. Better images of CB1 receptors in the brain may help improve our understanding of obesity and psychiatric disorders. This information may lead to better treatments. Objectives: \- To test how well a new radioactive chemical, 11C-SD5024, is taken up by the brain during imaging studies. Eligibility: \- Healthy volunteers between 18 and 50 years of age who are able to have positron emission tomography scans. Design: * All participants will be screened with a physical exam, medical history, and blood tests. * Participants will be in one of three groups for the study. Each group will receive 11C-SD5024 and have a different set of imaging studies. * Group 1 will have a magnetic resonance imaging (MRI) scan and PET scan of the brain. They will also have blood and urine tests. * Group 2 will have a whole-body PET scan, as well as blood and urine tests. * Group 3 will have an MRI scan of the brain, followed by two PET scans of the brain. They will also have blood and urine tests. The two PET scans can happen on the same day or on two different days.
Key facts
- Study ID
- NCT01399398
- Run by
- National Institute of Mental Health (NIMH)
- People needed
- 8
- Starts
- 2011-06-22
- Expected to finish
- 2013-12-18
- Last updated by the study team
- 2019-11-29
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- Any recent or past history of psychiatric illness or severe systemic disease based on history and physical exam.
- Serious medical illness likely to modify brain anatomy and/or physiology (head trauma, past brain surgery, neurological disorders such as epilepsy, Parkinson disease, and psychiatric disorders such as schizophrenia and depression)
- Any current substance or alcohol abuse, with the exception of nicotine.
- Positive urine toxicology screen
- Radiation exposure from participation in other research protocols in the last year such that the additional radiation exposure from this protocol would exceed annual limits.
- Pregnant or breastfeeding.
- Claustrophobia (applies to Parts 1 and 3 only).
- Metallic (ferromagnetic) implants, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, shrapnel fragments, and possible small metal fragments in the eye (applies to Parts 1 and 3 only).
- Unable to lie flat on back for up to 2.5 hours.
Where it is running
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.